Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive phase 2/3 trial of sarilumab in hospitalized adults with severe or critical COVID-19
MOH_2020-04-01_008818Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sanofi. Primary endpoints: Time to alleviation of predefined COVID-19 symptoms, Clinical efficacy versus control and 1 more. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2020-04-01_008818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-01_008818.